Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H. Mueller S, et al. Among authors: nejo t. J Clin Invest. 2020 Dec 1;130(12):6325-6337. doi: 10.1172/JCI140378. J Clin Invest. 2020. PMID: 32817593 Free PMC article. Clinical Trial.
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Ogino H, et al. Among authors: nejo t. J Clin Invest. 2022 Feb 1;132(3):e151239. doi: 10.1172/JCI151239. J Clin Invest. 2022. PMID: 34882581 Free PMC article. Clinical Trial.
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H. Mueller S, et al. Among authors: nejo t. J Clin Invest. 2022 Jun 15;132(12):e162283. doi: 10.1172/JCI162283. J Clin Invest. 2022. PMID: 35703183 Free PMC article. No abstract available.
Tumor antigens in glioma.
Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. Nejo T, et al. Semin Immunol. 2020 Feb;47:101385. doi: 10.1016/j.smim.2020.101385. Epub 2020 Feb 6. Semin Immunol. 2020. PMID: 32037183 Review.
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H. Chuntova P, et al. Among authors: nejo t. J Immunother Cancer. 2022 May;10(5):e004644. doi: 10.1136/jitc-2022-004644. J Immunother Cancer. 2022. PMID: 35606087 Free PMC article.
The evolution of alternative splicing in glioblastoma under therapy.
Wang L, Shamardani K, Babikir H, Catalan F, Nejo T, Chang S, Phillips JJ, Okada H, Diaz AA. Wang L, et al. Among authors: nejo t. Genome Biol. 2021 Jan 26;22(1):48. doi: 10.1186/s13059-021-02259-5. Genome Biol. 2021. PMID: 33499924 Free PMC article.
Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H. Chuntova P, et al. Among authors: nejo t. Neuro Oncol. 2022 Feb 1;24(2):259-272. doi: 10.1093/neuonc/noab182. Neuro Oncol. 2022. PMID: 34347086 Free PMC article.
Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, Takayanagi S, Hana T, Takahashi S, Kitagawa Y, Koike T, Kobayashi Y, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Narita Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Mukasa A, Saito N, Kakimi K. Nejo T, et al. Cancer Immunol Res. 2019 Jul;7(7):1148-1161. doi: 10.1158/2326-6066.CIR-18-0599. Epub 2019 May 14. Cancer Immunol Res. 2019. PMID: 31088845
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Matsushita H, et al. Among authors: nejo t. J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375. J Immunother Cancer. 2020. PMID: 32461346 Free PMC article.
38 results